HR0138LRB102 17334 MST 22824 r

1
HOUSE RESOLUTION

 
2    WHEREAS, Precision medicine, which is also called
3personalized health care or individualized medicine, is an
4evolving field in which healthcare providers use analysis of a
5patient's biospecimen, known as biomarker testing, to
6determine which medical treatments will work best for each
7patient; and
 
8    WHEREAS, By combining the data from biomarker testing with
9an individual's medical history, circumstances, and values,
10healthcare providers can direct a patient to targeted
11treatment, which benefits both patients and the overall
12healthcare system; and
 
13    WHEREAS, The field of precision medicine holds great
14promise in ensuring the delivery of the right treatment to the
15right patient at the right time; and
 
16    WHEREAS, Sixty percent of treatments in preclinical
17development rely on biomarker data; and
 
18    WHEREAS, Biomedicine and the understanding of the
19characteristics of a patient's disease that informs precision
20medicine is evolving rapidly; and
 

 

 

HR0138- 2 -LRB102 17334 MST 22824 r

1    WHEREAS, Healthcare providers are increasingly gaining
2access to new technologies, such as biomarker testing, that
3can help identify gene mutations, alterations, or protein
4expressions specific to individual patients; and
 
5    WHEREAS, Health outcomes are improved through the use of
6precision medicine; for example, patients with certain types
7of lung cancer who received biomarker testing had a 28 percent
8reduction in mortality; and
 
9    WHEREAS, The National Academy of Medicine considers
10biomarker tests to be "key to unlocking the promise" of
11personalized health care; and
 
12    WHEREAS, Biomarker testing is available for an
13ever-increasing range of conditions and diseases, but patient
14access to these tests is not keeping pace with the rate of
15innovation; and
 
16    WHEREAS, A lack of awareness among providers and patients,
17a lack of common terminology, and deficient coverage policies
18by both public and private payers are preventing effective
19adoption and integration of biomarker testing into precision
20medicine and appropriate awareness and education about the
21ways biomarker testing can be used to support diagnosis,
22treatment, and monitoring of patients in a personalized way;

 

 

HR0138- 3 -LRB102 17334 MST 22824 r

1and
 
2    WHEREAS, The Illinois Department of Public Health and
3other relevant partners seek to promote awareness, education,
4and action related to improving access to biomarker testing;
5therefore, be it
 
6    RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
7HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
8we declare March 2021 as "Precision Medicine and Biomarker
9Testing Awareness Month" to raise awareness, encourage
10education, and improve understanding of the ways biomarker
11testing can be used to support diagnosis, treatment, and
12monitoring of patients in a personalized way and the
13importance of ensuring access to these promising technologies.